TY - JOUR
T1 - Oleic acid biosynthesis in Plasmodium falciparum
T2 - Characterization of the stearoyl-CoA desaturase and investigation as a potential therapeutic target
AU - Gratraud, Paul
AU - Huws, Enlli
AU - Falkard, Brie
AU - Adjalley, Sophie
AU - Fidock, David A.
AU - Berry, Laurence
AU - Jacobs, William R.
AU - Baird, Mark S.
AU - Vial, Henri
AU - Kremer, Laurent
PY - 2009/9/3
Y1 - 2009/9/3
N2 - Background: Plasmodium falciparum parasitization of erythrocytes causes a substantial increase in the levels of intracellular fatty acids, notably oleic acid. How parasites acquire this monounsaturated fatty acid has remained enigmatic. Here, we report on the biochemical and enzymatic characterization of stearoyl-CoA desaturase (SCD) in P. falciparum. Methodology/Principal Findings: Metabolic labeling experiments allowed us to demonstrate the production of oleic acid from stearic acid both in lysates of parasites incubated with [14C]-stearoyl-CoA and in parasite-infected erythrocytes labeled with [14C]-stearic acid. Optimal SCD activity was detected in schizonts, the stage of maximal membrane synthesis. This activity correlated with a late trophozoite stage-specific induction of PFE0555w transcripts. PFE0555w harbors a typical SCD signature. Similar to mammalian SCDs, this protein was found to be associated with the endoplasmic reticulum, as determined with PFE0555w-GFP tagged transgenic P. falciparum. Importantly, these parasites exhibited increased rates of stearic to oleic acid conversion, providing additional evidence that PFE0555w encodes the plasmodial SCD (PfSCD). These findings prompted us to assess the activity of sterculic acid analogues, known to be specific Δ9-desaturase inhibitors. Methyl sterculate inhibited the synthesis of oleic acid both with parasite lysates and infected erythrocytes, most likely by targeting PfSCD. This compound exhibited significant, rapid and irreversible antimalarial activity against asexual blood stages. This parasiticidal effect was antagonized by oleic acid. Conclusion/Significance: Our study provides evidence that parasite-mediated fatty acid modification is important for blood-stage survival and provides a new strategy to develop a novel antimalarial therapeutic based on the inhibition of PfSCD.
AB - Background: Plasmodium falciparum parasitization of erythrocytes causes a substantial increase in the levels of intracellular fatty acids, notably oleic acid. How parasites acquire this monounsaturated fatty acid has remained enigmatic. Here, we report on the biochemical and enzymatic characterization of stearoyl-CoA desaturase (SCD) in P. falciparum. Methodology/Principal Findings: Metabolic labeling experiments allowed us to demonstrate the production of oleic acid from stearic acid both in lysates of parasites incubated with [14C]-stearoyl-CoA and in parasite-infected erythrocytes labeled with [14C]-stearic acid. Optimal SCD activity was detected in schizonts, the stage of maximal membrane synthesis. This activity correlated with a late trophozoite stage-specific induction of PFE0555w transcripts. PFE0555w harbors a typical SCD signature. Similar to mammalian SCDs, this protein was found to be associated with the endoplasmic reticulum, as determined with PFE0555w-GFP tagged transgenic P. falciparum. Importantly, these parasites exhibited increased rates of stearic to oleic acid conversion, providing additional evidence that PFE0555w encodes the plasmodial SCD (PfSCD). These findings prompted us to assess the activity of sterculic acid analogues, known to be specific Δ9-desaturase inhibitors. Methyl sterculate inhibited the synthesis of oleic acid both with parasite lysates and infected erythrocytes, most likely by targeting PfSCD. This compound exhibited significant, rapid and irreversible antimalarial activity against asexual blood stages. This parasiticidal effect was antagonized by oleic acid. Conclusion/Significance: Our study provides evidence that parasite-mediated fatty acid modification is important for blood-stage survival and provides a new strategy to develop a novel antimalarial therapeutic based on the inhibition of PfSCD.
UR - http://www.scopus.com/inward/record.url?scp=70249092571&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70249092571&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0006889
DO - 10.1371/journal.pone.0006889
M3 - Article
C2 - 19707292
AN - SCOPUS:70249092571
SN - 1932-6203
VL - 4
JO - PLoS One
JF - PLoS One
IS - 9
M1 - e6889
ER -